Choisissez votre fonte :
 Arimo
 Merriweather
 Mukta Malar
 Open Sans Condensed
 Rokkitt
 Source Sans Pro
 Se connecter


 Français 
 English 
 Português 
 Español 

[Valid RSS] RSS
bar

Base de données - (CIANE)

Présentation de cette base de données documentaires (site du CIANE)
Actuellement 3111 fiches
Chaîne YouTube (tutoriel)

https://ciane.net/id=2303

Créée le : 03 Jan 2009
Modifiée le : 03 Jan 2009

 Modifier cette fiche
Ne suivez ce lien que si vous possédez un mot de passe d’éditeur !


Partager : Facebook logo   Tweeter logo   Spécialisé

Notice bibliographique (sans auteurs) :

Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003510.Click here to read

Auteur·e(s) :

Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P.

Année de publication :

2007

URL(s) :

http://mrw.interscience.wiley.com/cochrane/clsysre…

Résumé (français)  :

Abstract (English)  :

BACKGROUND: Antiretroviral drugs (ARV) reduce viral replication and can reduce mother-to-child transmission of HIV either by lowing plasma viral load in pregnant women or through post-exposure prophylaxis in their newborns. In rich countries, highly active antiretroviral therapy (HAART) has reduced the vertical transmission rates to around 1-2%, but HAART is not yet widely available in low and middle income countries. In these countries, various simpler and less costly antiretroviral regimens have been offered to pregnant women or to their newborn babies, or to both.

OBJECTIVES: To determine whether, and to what extent, antiretroviral regimens aimed at decreasing the risk of mother-to-child transmission of HIV infection achieve a clinically useful decrease in transmission risk, and what effect these interventions have on maternal and infant mortality and morbidity.

SEARCH STRATEGY: We sought to identify all relevant studies regardless of language or publication status by searching the Cochrane HIV/AIDS Review Group Trials Register, The Cochrane Library, Medline, EMBASE and AIDSearch and relevant conference abstracts. We also contacted research organizations and experts in the field for unpublished and ongoing studies. The original review search strategy was updated in 2006.

SELECTION CRITERIA: Randomised controlled trials of any antiretroviral regimen aimed at decreasing the risk of mother-to-child transmission of HIV infection compared with placebo or no treatment.

DATA COLLECTION AND ANALYSIS: Two authors independently selected relevant studies, extracted data and assessed trial quality. For the primary outcomes, we used survival analysis to estimate the probability of infants being infected with HIV (the observed proportion) at various specific time-points and calculated efficacy at a specific time as the relative reduction in the proportion infected. Efficacy, at a specific time, is defined as the preventive fraction in the exposed group compared to the reference group, which is the relative reduction in the proportion infected: 1-(Re/Rf). For those studies where efficacy and hence confidence intervals were not calculated, we calculated the approximate confidence intervals for the efficacy using recommended methods. For analysis of results that are not based on survival analyses we present the relative risk for each trial outcome based on the number randomised. No meta-analysis was conducted as no trial assessed the identical drug regimens.

MAIN RESULTS: Eighteen trials including 14,398 participants conducted in 16 countries were eligible for inclusion in the review.

[…]

AUTHORS’ CONCLUSION: Short courses of antiretroviral drugs are effective for reducing mother-to-child transmission of HIV and are not associated with any safety concerns in the short-term. A combination of ZDV and 3TC given to mothers in the antenatal, intrapartum and postpartum periods and to babies for a week after delivery or a single dose of NVP given to mothers in labour and babies immediately after birth may be most effective. Where HIV infected women present late for delivery, post-exposure prophylaxis with a single dose of NVP immediately after birth plus ZDV for the first 6 weeks of life is beneficial. The long term implications of the emergence of resistant mutations following the use of these regimens require further study.

Sumário (português)  :

Resumen (español)  :

Remarques :

Argument (français) :

Argument (English):

Researchers theorized that a course of antiretroviral drugs (ARV) given to pregnant women and their newborn babies could reduce the risk of mother-to-child transmission.

Argumento (português):

Argumento (español):

Mots-clés :

➡ VIH

Auteur·e de cette fiche :

Bernard Bel — 03 Jan 2009

Discussion (afficher uniquement le français)
 
➡ Réservé aux utilisateurs identifiés



 J'ai lu la charte des discussions et j'en accepte les conditions (voir la charte)

barre

Autre requête experte --- Autre requête simple

Création d'une fiche --- Importation de fiches

Gestion des utilisateurs --- Sauvegarder la base de données --- Contact

bar

Cette base de données créée par l'Alliance francophone pour l'accouchement respecté est gérée
par le Collectif interassociatif autour de la naissance (CIANE, https://ciane.net).
Elle est alimentée par les contributions de bénévoles intéressés par le partage des informations scientifiques.
Si vous approuvez ce projet, vous pouvez nous aider de plusieurs manières :
(1) devenir contributeur sur cette base, si vous avez un peu d'expérience en documentation
(2) ou soutenir financièrement le CIANE (voir ci-dessous)
(3) ou devenir membre d'une association affiliée au CIANE.
Connectez-vous ou créez un compte pour suivre les modifications ou devenir éditrice.
Contactez bibli(arobase)ciane.net pour plus d'informations.

Valid CSS! Valid HTML!
Nos ressources servent principalement à couvrir les frais d’hébergement des sites
et bases de données, l’impression de flyers et occasionnellement des frais de transport.
Les donateurs particuliers peuvent demander un reçu fiscal du CIANE donnant droit, en France, à une
réduction d’impôt égale à 66 % du montant dans la limite de 20% du revenu imposable (voir texte)